Kornimate/medical-research-clean huggingface dataset:
yellow 560 microscope for intraoperative visualization of fluorescein stained intracranial lesions

Conditions: Adult Intracranial Neoplasm; Vascular: Intracranial

Summary: the purpose of this study is to evaluate the effectiveness of using fluorescein sodium and the yellow 560 microscope to aid in treatment of intracranial tumors and vascular lesions.

the purpose of this study is to evaluate the effectiveness of using fluorescein sodium and the yellow 560 microscope to aid in treatment of intracranial tumors and vascular lesions. the objectives of this study aim to investigate the use of fluorescein in assisting with evaluating complete tumor removal and thorough treatment of intracranial vascular lesions as well as tumor biopsy procedures. the hypothesis is that fluorescein sodium will help surgeons better identify residual tumor and vascular lesions and its use will allow surgeons to obtain better surgical results and prognostic outcomes.

Eligibility criteria:
inclusion criteria: * age 18 years or older. * diagnosed by preoperative imaging modalities to have a brain tumor or vascular lesions (aneurysm, arteriovenous malformation or arteriovenous fistula) requiring surgical intervention. * the patient is determined by a board certified neurosurgeon (above mentioned neurosurgeons) to benefit from the application of fluorescein sodium intraoperatively * patient or legally authorized representative provides written informed consent to enroll in this study. exclusion criteria: * known allergic reaction to fluorescein sodium. * children. * prisoners. * students. * infection of the central nervous system or other sites. * hemodynamic instability or significant impairments in circulation. * concomitant treatment with other investigational drugs. * any uncontrolled condition unrelated to the neurosurgical disease. * history of psychiatric, additive, or any other disorder that compromises the ability to provide informed consent or comply with study protocols. * participation on other clinical trials during the last thirty days. * pregnant patients. * patients unable to discontinue medications that affect fluorescein metabolism.
epigenetic markers of b-cell function in low birth weight infants

Conditions: Low Birth Weight; Small for Gestational Age; Immunodeficiency

Summary: low birth weight (lbw) status (\< 10% for gestational age at birth) is associated with increased risk for diseases such as type ii diabetes mellitus, hypertension, chronic obstructive pulmonary disease and coronary artery disease in adults, and represents one example of the "fetal onset of adult disease" hypothesis. recent data strongly associates lbw status with impaired innate and adaptive immunity leading to increased risk for severe infections during adolescence or early adulthood. animal studies suggest that the ratio of certain b lymphocyte subpopulations, the b1a and b1b cells, determines whether deficits in immunity occur. this study will determine the ratio of b1b to b1a lymphocyte subpopulations in the cord blood of infants born lbw in the late preterm to term gestations (\> 34 weeks at birth) and compare those ratios with those of normal birth weight (nbw) controls in a nested case control study design. furthermore, animal studies suggest that the expression patterns of cd5 and cd19 proteins determines the cellular phenotype of the b lymphocyte, that of a b1a or a b1b cell, and that the regulatory regions controlling their expression are epigenetically vulnerable. the investigators will therefore isolate dna and rna from both b lymphocyte subpopulations and determine whether epigenetic changes to the regulatory regions of the genes coding for cd5 and cd19 protein expression occur in lbw lymphocyte subpopulations as compared to the lymphocytes from nbw infants. this proposal will be the first human study to examine epigenetic determination of a maladaptive phenotype following lbw status at birth in a specific cell type leading to a specific impairment of innate and adaptive immunity.


Eligibility criteria:
inclusion criteria: * infants delivered at university of utah health sciences center * for lbw group: * gestational age \> or = to 34 0/7 weeks * birth weight \< or = to 10% for gestational age * for nbw group: * term infant controls delivered without complication * adequate cord blood sample obtained directly after birth * parents or guardians must have signed informed consent exclusion criteria: * infants with major congenital anomalies will be excluded

Keywords: low birth weight small for gestational age b-cell function epigenetics b1a b1b cd19 cd5
an open-label, randomized phase ii study to evaluate the efficacy of auy922 vs pemetrexed or docetaxel in nsclc patients with egfr mutations

Conditions: Advanced Non Small Cell Lung Cancer (NSCLC)

Summary: the purpose of this study was to determine if auy922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had egfr mutations. the primary purpose of this study was to compare the efficacy of auy922, when administered i.v. on a once-weekly schedule at 70 mg/m2, versus docetaxel or pemetrexed in adult patients with advanced nsclc, whose tumors harbored egfr activating mutations, and had developed resistance to egfr tki.


Eligibility criteria:
inclusion criteria: 1. patients with histologically or cytologically documented, locally advanced (stage iiib who are not amenable to combined modality treatment) or recurrent or metastatic (stage iv) non-small cell lung cancer. 2. patients must have egfr gene mutation in their tumors. this can be source - documented by one of the following: • provide a pathology report that indicates the patient's tumor had egfr activating mutation in the past. or: • perform testing (local or central) in an archival tumor or a fresh baseline biopsy tumor tissue to show the presence of egfr activating mutation. 3. patients must have documented clinical benefit (cr, pr, or patients with sd for 6 months or greater) on prior egfr tki (e.g. erlotinib or gefitinib) followed by documented progression according to recist. 4. patients must have received prior platinum containing treatment. 5. who performance status of 0-1 exclusion criteria: 1. patients who have received more than two prior lines of antineoplastic therapy for advanced disease. chemotherapy administered as neoadjuvant or adjuvant treatment more than six months prior to study enrollment is not considered a prior line of therapy for purposes of this study. 2. evidence of spinal cord compression or current evidence of cns metastases. screening ct/mri of the brain is mandatory. note: patients who have been treated for cns metastases by radiation or gamma knife surgery, who been stable for at least 2 months and have discontinued high dose corticosteroids will be eligible for protocol participation 3. prior treatment with an hsp90 inhibitor

Keywords: non-small cell lung carcinoma (nsclc) treatment of lung cancer after first metastasis lung cancer lung adenocarcinoma squamous cell lung carcinoma large-cell lung carcinoma non small cell lung carcinoma non small cell lung cancer non-small cell lung cancer nsclc large cell lung carcinoma large cell lung cancer hsp90 auy922 pemetrexed docetaxel egfr tki egfr mutations
frozen embryo transfer in natural and hormonal replacement cycles

Conditions: Infertility

Summary: this study is a prospective randomized controlled trial to compare the pregnancy outcomes of frozen embryo transfer in natural and hormonal replacement cycles. the study population consisted of all infertile women with regular menstrual cycles who will undergo ivf/icsi and frozen embryo transfer in reproductive biomedicine research center, royan institute, tehran iran.

in this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hcg for ovulation induction) or hormonal cycle (with or without administration of gnrh-a) in natural cycle without hcg, daily monitoring of urinary lh is started from day eight of the cycle and frozen-thawed embryo transfer is planned 3-5 days after detection of lh surge, observing mature follicles in ultrasound and endometrial thickness over 7mm for cleavage embryos. in natural cycle with hcg, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000iu hcg is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage. in group 3, injection of gnrh agonist (superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral estradiol valerate and after 7 days if endometrial thickness is adequate, estradiol administration will be continued with the same dose and 100mg progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of estradiol till favourable endometrial thickness is achieved. in the hormonal group without gnrh-a, endometrial preparation will be started with daily administration of 6 mg estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. then treatment will be continued similar to the 3rd group.

Eligibility criteria:
inclusion criteria: 1. patients with regular mensturation cycles 2. age 20-37 years 3. patients who underwent long protocol 4. body mass index (bmi) ≤ 30 kg/m2 5. patients who will undergo frozen embryo transfer for the first time exclusion criteria: 1. oocyte or embryo donation cycles 2. uterine diseases or malformations 3. hyper prolactinemia 4. thyroid disorders 5. tuberculosis 6. recurrent abortion history 7. severe endometriosis 8. ovulation disorders

Keywords: infertility froze emberyo transfer hormone replacement
protocols for magnesium sulfate maintenance dose in overweight and obese women diagnosed with preeclampsia

Conditions: Severe Preeclampsia

Summary: there is still no evidence of the appropriate dose to be used. serum magnesium sulfate concentration is not measured regularly, thus we may be using sub-therapeutic level or reaching a toxic level.overweight and obese women have different pharmacokinetics and different drug distribution, therefore, they may need higher doses of magnesium sulfate to reach therapeutic level.

magnesium sulfate is used in pre-eclampsia to prevent seizures, it is administered in the form of a loading dose and maintenance dose. maintenance dose of magnesium sulfate in pre-eclampsia varies in literature (1-3gms/hour). there is still no evidence of the appropriate dose to be used. serum magnesium sulfate concentration is not measured regularly, thus we may be using sub-therapeutic level or reaching a toxic level.overweight and obese women have different pharmacokinetics and different drug distribution, therefore, they may need higher doses of magnesium sulfate to reach therapeutic level. this study will evaluate whether overweight and obese women need higher maintenance doses to reach therapeutic level of magnesium sulfate in serum.preeclampsia is a serious pregnancy complication characterized by hypertension, proteinuria and signs of damage to another organ system, often the kidneys, occurring after 20 weeks of gestation

Eligibility criteria:
inclusion criteria: women diagnosed with spet as per criteria of nice, 2023 guidance * age 20-40 years * bmi \>25kg/m2 * gestational age \> 28 weeks exclusion criteria: * intrauterine fetal death (iufd) * hemolysis - elevated liver enzymes - low platelets syndrome (hellp) * contraindication to magnesium sulfate such as myasthenia gravis, severe renal failure, cardiac ischemia, and heart block * serum creatinine levels greater than 1.1 mg/dl. * women refusing to participate in the study.
the influences of malnutrition and inflammation complex syndrome in hemodialysis patients

Conditions: Hemodialysis; Malnutrition; Inflammation; Myocardial Ischemia; Cerebrovascular Accident

Summary: the purpose of this study is to explore the severity of malnutrition and inflammation in taiwanese hemodialysis patients.

cardiovascular disease is the major of cause of mortality of hemodialysis patients. in addition to diabetes and hypertension, malnutrition and chronic inflammation are well-known to be major risk factors of cardiovascular diseases in normal population. for detecting the malnutrition and chronic inflammation and understanding the exact influences to hemodialysis patients, we conduct this study. we will collect the biochemical parameters, inflammatory markers, lipid parameters, hematologic parameters, and genomic dna of patients. then we will prospectively record the hospitalization, cardiovascular events, complications of arteriovenous fistula/graft, and mortality. according to the above results, we try to explore the exact role of malnutrition and inflammation in hemodialysis patients.

Eligibility criteria:
inclusion criteria: * patients who have received hemodialysis therapy for more than three months exclusion criteria: * having active infection diseases now * patients who have a malignancy * had cardiovascular events in recent three months

Keywords: hemodialysis malnutrition inflammation
the influence of medical clowns on the performance of pulmonary function tests among preschooler children

Conditions: Asthma; Pneumonia

Summary: medical clowns are known to assist in relaxing children and allowing better cooperation during performance of medical procedures. the ability of medical clowns to improve the motivation of children to perform active tasks was never examined to date. the investigators would like to examine the influence of the clowns' presence on the performance of pulmonary function test.

the investigators would like to evaluate the performance of pulmonary function tests among preschool children aged 3-6 years. overall 200 children will participate. the children will perform pulmonary function test without a clown present. about an hour later half of them will perform the exam again with a medical clown assistance and the second half will repeat the examination without a clown present the differences between the performance will be evaluated.

Eligibility criteria:
inclusion criteria: * children visiting the pediatric pulmonology clinic * parents signed informed consent exclusion criteria: * medical or neurological diseases not allowing performance of pulmonary function tests * parents refusal
a study of tdcs for swallowing difficulties in stroke patients

Conditions: Stroke

Summary: the primary objective of this study is to investigate whether the dual transcranial direct current stimulation(tdcs) improves the swallowing function of stroke patients.

120 patients were recruited and randomized to receive either real or sham-tdcs. real experimental groups were divided into three types; anode-anode dual stimulation group, anode-cathode dual stimulation group, single stimulation group. 20-minutes session of the stimulation were applied 5 times a weeks for 2 weeks at pharyngeal motor cortex of affected or non-affected site. the patients were evaluated at baseline, immediately and 2 weeks after tdcs.

Eligibility criteria:
inclusion criteria * subjects who have diagnosed as primary stroke by physician's physical exam or radiologic diagnosis * subjects who have cortical or subcortical brain lesion * subjects who was diagnosed as stroke within 6 months * subjects ages from 18years to 80years old * subjects who have less than 5 points of doss score due to swallowing difficulty from cns injury * subjects who is possible to receive swallowing function intervention 5 days a week * subjects who understand the purpose of the study and acquired the consent of the patient or caregiver * subjects who had no effect from brain stimulation or electrical stimulation therapy exclusion criteria * subjects who have pre-existing and active major neurological disease * subjects who have pre-existing and active major psychiatric disease, such as major depression, schizophrenia, bipolar disease, or dementia * subjects who have brain lesion except cortex or subcortex area * subjects who have any metal component after brain surgery, low threshold to pain, history of seizure * subjects who is estimated as not appropriate for the study by the investigators
study on the tolerability of duloxetine in depressed patients with parkinson's disease

Conditions: Major Depressive Disorder; Idiopathic Parkinson Disease

Summary: this study aims to assess the tolerability of duloxetine, 60mg once daily, in open label fashion, in depressed patients with parkinson's disease during 12 weeks treatment.


Eligibility criteria:
inclusion criteria: * are outpatients, male or female, 30 through 75 years of age * meet diagnostic criteria for major depression episode and a clinical diagnosis of idiopathic parkinson's disease * have a clinician-rated 17-item hamilton depression rating scale (hamd17) total score greater than or equal to 15, a beck depression inventory (bdi) total score greater than or equal to 13 and a clinical global impression of severity (cgi-s) score greater than or equal to 3 at both visit 1 and visit 2 * have satisfactory cognitive function * have been held on stable dosage of antiparkinsonian medications for at least 4 weeks immediately prior to visit 1 exclusion criteria: * any current primary psychiatric diagnosis other than major depressive episode, and any personality disorder that could interfere with the compliance with the study protocol * atypical or secondary parkinsonism due to drugs or diseases with features of parkinson's disease * motor conditions for which it is to be expected to change the antiparkinsonian treatment during the course of the study * clinically significant laboratory abnormalities or serious, unstable medical illness * lack of response of current episode to two or more adequate courses of antidepressant therapy
influence of dental occlusion on the performance of high level rowers (iodpr)

Conditions: Dental Occlusion, Traumatic

Summary: monocentric, prospective, randomized, open-label, cross-over study.

current literature data suggest that dental occlusion has an influence on postural control in the general population, and more markedly in high-level athletes. the link between dental occlusion and the postural stability of top athletes has been studied in several disciplines such as basketball, shooting, golf and running. there is currently no data in the field of rowing. but this sport requires optimal postural control for synchronous and symmetrical muscle solicitation. the present study aims to evaluate the influence of dental occlusion on postural stability and the performance of high level rowers. our assumptions are as follows: * occlusal disturbance alters the muscular power developed by high level rowers * occlusal disturbance alters the static postural stability of high level rowers

Eligibility criteria:
inclusion criteria: * high level rower, part of the lille rowing hope pole; * at least 15 years old; * training at the centre de ressources, d'expertise et de performance sportive (creps) de wattignies during the period from 01/09/2017 to 31/10/2017; * having at least 28 natural or prosthetic teeth in occlusion; * not having consumed alcohol in the last 24 hours before the recordings; * whose parents have given free, informed and written consent for minors; * having given free and informed consent, in writing supplemented by the consent of at least one holder of parental authority, if he is a minor; * affiliated, himself or through his parents if he is a minor, to a social security scheme. exclusion criteria: * current antecedent(s) or pathology(s) likely to disturb the balance: neurological, ear nose and throat, ophthalmological, orthopedic; * temporomandibular joint disorder (s) (pain and / or noise); * orofacial symptoms (headache, tinnitus, facial myalgia, bruxism); * dental and / or periodontal care in progress; * chronic pain requiring daily use of analgesics for more than three months; * pregnant or lactating woman; * concurrent participation in another study; * major persons subject to legal protection (safeguard of justice, guardianship, tutorship) and persons deprived of their liberty.

Keywords: young elite rowers
identifying ideal reimbursement "dose" to reduce clinical trial-related financial toxicity

Conditions: Breast Cancer

Summary: the goal of this clinical trial is to identify the recommended financial reimbursement amount for women with breast cancer enrolled in a clinical trial. the main questions it aims to answer are: 1. what is the recommended financial reimbursement amount in trial-enrolled women with breast cancer experiencing financial toxicity? 2. what do patients think about receiving a reimbursement for trial-incurred expenses? participants will receive a monthly reimbursement to compensate for their trial-incurred expenses in cohorts, which will de-escalate for the next participant cohort if patients find the reimbursement dose suitable (negative financial toxicity screen, reimbursement dose deemed acceptable/appropriate). researchers will also use qualitative interviews to explore patient perceptions of the trial reimbursements.

our overall objective is to innovatively use a dose-finding approach to identify the recommended reimbursement amount for women with breast cancer enrolled in a clinical trial. we hypothesize that optimal reimbursement for trial-related expenses will decrease patient financial toxicity and increase trial retention. the rationale is that understanding the impact of reimbursement for trial-related costs will aid in addressing socioeconomic barriers to trial participation, thus allowing for more diversity in trial enrollment and ensuring equitable efficacy of cancer treatments when used in real-world clinical settings. aim 1. identify the recommended reimbursement amount in trial-enrolled women with breast cancer experiencing financial toxicity. we propose a pilot reimbursement dose de-escalation trial (continual reassessment method design; n=30) testing a monthly reimbursement for trial-enrolled patients who screen positive for financial toxicity. we will oversample patients who are black (50%) or residing in rural locations (50%). monthly patient-reported financial toxicity and reimbursement acceptability and appropriateness will be captured. reimbursement dose will start at $1000 and de-escalate if patients find the reimbursement dose suitable (negative financial toxicity screen, reimbursement dose deemed acceptable/appropriate). aim 2. explore patient perceptions of trial reimbursement amounts. using semi-structured interviews, we will explore the effects of reimbursement on specific covered and uncovered trial-related costs, financial toxicity, and current retention and future participation in clinical trials.

Eligibility criteria:
inclusion criteria: * participants will be women with breast cancer currently enrolled in the investigation of serial studies to predict your therapeutic response with imaging and molecular analysis (i-spy trial 2) at the uab medical oncology clinic. exclusion criteria: * non-english speakers * males * females without cancer * female cancer patients not enrolled in the i-spy trial 2